BATON ROUGE, La., March 13, 2017 -- Amedisys, Inc. (NASDAQ:AMED) today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the 27th Annual Oppenheimer Healthcare Conference in New York City, NY on Tuesday, March 21, 2017.
The presentation will begin at 2:45 p.m. Eastern Time. To access a live webcast of the Amedisys presentation, please log on through our website at http://investors.amedisys.com.
About Amedisys
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 16,000 employees, in 421 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 340,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.
Contact: Amedisys, Inc. David Castille Managing Director, Finance 225.299.3665 [email protected]


NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 



